Related Experiment Video
Updated: Jul 19, 2026

Murine Aortic Crush Injury: An Efficient In Vivo Model of Smooth Muscle Cell Proliferation and Endothelial Function
Published on: June 11, 2017
Vascular disrupting agents.
1Medicinal Chemistry Department, Albany Molecular Research, Inc., PO Box 15098, Albany, NY 12212-5098, USA. john.lippert@albmolecular.com
Vascular disrupting agents (VDAs) offer a novel cancer treatment by collapsing tumor blood vessels, unlike antiangiogenesis drugs. This review covers six small molecule VDAs and their clinical progress.
Area of Science:
- Oncology
- Pharmacology
- Vascular Biology
Background:
- Vascular targeting agents (VTAs) and vascular disrupting agents (VDAs) represent distinct cancer treatment strategies.
- VTAs inhibit angiogenesis, preventing new blood vessel formation.
- VDAs target and collapse existing tumor vasculature.
Purpose of the Study:
- To differentiate VDAs from VTAs based on their mechanisms of action.
- To review six specific small molecule VDAs.
- To discuss their synthesis, biological activity, and clinical status.
Main Methods:
- Literature review of small molecule VDAs.
- Analysis of VDA mechanisms of action.
- Summary of clinical trial data for selected VDAs.
Main Results:
- VDAs induce rapid vascular collapse within solid tumors.
- This collapse deprives tumors of essential oxygen and nutrients.
- Six VDAs (DMXAA, ZD6126, TZT1027, CA4P, AVE8062, Oxi4503) are detailed.
Conclusions:
- VDAs present a promising approach for treating established tumors.
- Further research into VDA synthesis and clinical application is warranted.
- Understanding VDA mechanisms is crucial for effective cancer therapy.
More Related Videos
12:30Vascular Gene Transfer from Metallic Stent Surfaces Using Adenoviral Vectors Tethered through Hydrolysable Cross-linkers
Published on: August 12, 2014
10:56A Novel Three-dimensional Flow Chamber Device to Study Chemokine-directed Extravasation of Cells Circulating under Physiological Flow Conditions
Published on: July 15, 2013
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Vascular Spasm
Venous Thrombosis I: Introduction
Drugs that Destabilize Microtubules
Varicose Veins II: Diagnostic Studies and Interprofessional Care